An investigation for ivnestors investors of Innocoll Holdings PLC was announced concerning possible securities laws violations by Innocoll Holdings and certain of its directors and officers.
Investors who purchased shares of Innocoll Holdings PLC (NASDAQ:INNL), have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether a series of statements by Innocoll Holdings regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Innocoll Holdings PLC reported that its annual Total Revenue declined from $4.50 million in 2014 to $2.59 million in 2015 and that its Net Loss increased from $20.67 million in 2014 to $43.15 million in 2015.
On December 29, 2016, Innocoll Holdings PLC announced that it has received a Refusal to File letter from the United States Food and Drug Administration (“FDA”) for XARACOLL, the company’s product candidate for the treatment of postsurgical pain.
On January 19, 2017, NASDAQ:INNL shares closed at $0.692 per share.
Those who purchased NASDAQ:INNL shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego